InfluenCEF study : Clinical phenotype and duration of headache attributed to influenza infection

INTRODUCTION: Headache is a frequent symptom of infections. We aimed to characterize the clinical phenotype and duration of headache attributed to influenza infection.

METHODS: Prospective cohort study done in 53 primary care centers between January and April 2023. Patients were included if they had a confirmed influenza diagnosis, were older than 15 years and had a new-onset headache. Patients' demographics, prior medical history, headache phenotype and duration, associated symptoms and patients' outcomes were assessed. The International Classification of Headache Disorders criteria for headache attributed to a systemic viral infection, migraine and tension-type headache were assessed.

RESULTS: Of the 478 patients 75 fulfilled eligibility criteria. The mean age was 43, 56% were men, and 27% had a prior headache history. The headache phenotype was a bilateral headache (52%), with frontal topography (48%), pressing quality (61%), moderate intensity, rhinorrhea (79%), nasal congestion (76%), and photophobia (59%). All patients fulfilled headache attributed to acute systemic viral infection criteria, 43% fulfilled migraine criteria and 31% tension-type headache criteria. The median duration of the headache was four (Inter-quartile range: two-six) days.

CONCLUSION: The clinical phenotype of headache attributed to influenza infection was similar to other infections, with more pronounced cranial autonomic symptoms. The headache was an early symptom and was self-limited within a few days.Trial Registration: The study protocol is registered in ClinicalTrial.gov (NCT05704335).

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:43

Enthalten in:

Cephalalgia : an international journal of headache - 43(2023), 11 vom: 11. Nov., Seite 3331024231212900

Sprache:

Englisch

Beteiligte Personen:

García-Azorín, David [VerfasserIn]
Santana-López, Laura [VerfasserIn]
Lozano-Alonso, José Eugenio [VerfasserIn]
Ordax-Díez, Ana [VerfasserIn]
González-Osorio, Yésica [VerfasserIn]
Rojo-Rello, Silvia [VerfasserIn]
Eiros, José M [VerfasserIn]
Sánchez-Martínez, Javier [VerfasserIn]
Recio-García, Andrea [VerfasserIn]
Sierra-Mencía, Álvaro [VerfasserIn]
Sanz-Muñoz, Ivan [VerfasserIn]
Guerrero-Peral, Ángel Luis [VerfasserIn]

Links:

Volltext

Themen:

Anti-inflammatory agents
COVID-19
Clinical Study
Headache disorders
Journal Article
Migraine
Non-steroidal
Secondary
Virus diseases

Anmerkungen:

Date Completed 20.11.2023

Date Revised 27.11.2023

published: Print

ClinicalTrials.gov: NCT05704335

Citation Status MEDLINE

doi:

10.1177/03331024231212900

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM36442334X